Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evolent Health, Inc.EVH · Entity 5492 | 10% owner | May 19, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evolent Health, Inc.
Report date May 19, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 6,434,283 |
Reported balance
After 2017-05-19 transaction · row 1
1 source rowRow 1 · 2017-05-19 · Sale · Disposed 2,333,333 · Balance 6,434,283 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Werewolf Therapeutics, Inc.
Report date May 04, 2021 · Filed May 04, 2021
Section 16 reporting ended · disclosed 2021-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,097,756 |
Ending reported balance
After 2021-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-04 · Conversion · Acquired 823,945 · Balance 823,945 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Row 2 · 2021-05-04 · Conversion · Acquired 273,811 · Balance 1,097,756 F2: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-04 · Conversion · Disposed 7,142,857 · Balance 0 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-04 · Conversion · Disposed 2,373,701 · Balance 0 F2: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 2,373,701 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018109 · doc4.xml · derivative · entry 4 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 273,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.exercise_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · derivative.expiration_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 7,142,857 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018109 · doc4.xml · derivative · entry 3 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 823,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 273,811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018109 · doc4.xml · nonDerivative · entry 2 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,097,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:30 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 823,945 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018109 · doc4.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| May 19, 2017 Filed May 22, 2017 18:01 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock, par value $.01 per share | 2,333,333 | $24.30 | $56,699,991.90 |
DisclosureSEC source: 0001644244-17-000003 · primary_doc.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,434,283 Read SEC document |
| May 01, 2017 Filed May 3, 2017 18:17 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock, par value $.01 per share | 403,644 | $19.53 | $7,883,167.32 |
DisclosureSEC source: 0001644244-17-000002 · primary_doc.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,767,616 Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 21:17 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock, par value $.01 per share | 2,690,961 | $19.53 | $52,554,468.33 |
DisclosureSEC source: 0001644244-17-000001 · primary_doc.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,171,260 Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 20:11 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock, par value $.01 per share | 403,644 | $21.54 | $8,694,491.76 |
DisclosureSEC source: 0001644244-16-000003 · primary_doc.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,862,221 F1 · price: The price of $21.54 represents the public offering price of $22.50 per share of Class A Common Stock less the underwriters' discount of $0.96 per share. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:42 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock, par value $.01 per share | 2,460,307 | $21.54 | $52,995,012.78 |
DisclosureSEC source: 0001644244-16-000002 · primary_doc.xml · nonDerivative · entry 1 UPMC · CIK 0001644244 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,265,865 F1 · price: The price of $21.54 represents the public offering price of $22.50 per share of Class A Common Stock less the underwriters' discount of $0.96 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.